Guideline for postmarketing Chinese medicine pharmacoeconomic evaluation.
10.1007/s11655-014-1749-y
- Author:
Xin WANG
1
;
Zhi-Fei WANG
;
Yan-Ming XIE
;
Wen ZHANG
;
Xing LIAO
;
Yan-Peng CHANG
;
null
Author Information
1. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
- Publication Type:Journal Article
- MeSH:
Clinical Trials as Topic;
Cost-Benefit Analysis;
Economics, Pharmaceutical;
Guidelines as Topic;
Humans;
Pharmaceutical Preparations;
economics;
Product Surveillance, Postmarketing;
economics;
Statistics as Topic
- From:
Chinese journal of integrative medicine
2015;21(6):473-480
- CountryChina
- Language:English
-
Abstract:
Pharmacoeconomics is an important part of the postmarketing Chinese medicine (CM) evaluation, and postmarketing pharmacoeconomic evaluation can reveal the clinical and market value of CM. The purpose of establishing the guideline for pharmacoeconomic evaluation is to make the evaluation process and results regarding Chinese patent medicines both scientific and fair. Every country's guidelines for pharmacoeconomic evaluation act as reference guidelines, we have already drawn up the guideline that takes into account the special characteristics of CM; and these are in preparation for the postmarketing CM pharmacoeconomic evaluation.
